News Summary

• The FDA awarded priority review vouchers to two companies studying psilocybin — the active ingredient in magic mushrooms — for hard-to-treat forms of depression.
• A third company received a voucher for methylone, a drug related to MDMA, for post-traumatic stress disorder.
• The FDA did not name the companies in a press release announcing the news.
• The vouchers don’t guarantee approval, but instead mean that regulators will try to shorten their reviews from a period of months to weeks.